Page last updated: 2024-09-04

cyc 202 and Leukemia, Myeloid, Acute

cyc 202 has been researched along with Leukemia, Myeloid, Acute in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP	1
Duan, X; Gao, F; Rashid, A; Yang, M; Yen, A	1

Studies

Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP

Duan, X; Gao, F; Rashid, A; Yang, M; Yen, A

Other Studies

2 other study(ies) available for cyc 202 and Leukemia, Myeloid, Acute

Article	Year
The target landscape of clinical kinase drugs. Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays	2017
Roscovitine enhances All-trans retinoic acid (ATRA)-induced leukemia cell differentiation: Novel effects on signaling molecules for a putative Cdk2 inhibitor. Cellular signalling, 2020, Volume: 71 Topics: Cell Cycle Checkpoints; Cell Differentiation; Cell Proliferation; Down-Regulation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Myeloid Cells; NADPH Oxidases; Phosphorylation; Principal Component Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins c-vav; Respiratory Burst; Roscovitine; Signal Transduction; src-Family Kinases; Tretinoin; Up-Regulation	2020

Article

Year

The target landscape of clinical kinase drugs.

Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017

Roscovitine enhances All-trans retinoic acid (ATRA)-induced leukemia cell differentiation: Novel effects on signaling molecules for a putative Cdk2 inhibitor.

Cellular signalling, 2020, Volume: 71

Topics: Cell Cycle Checkpoints; Cell Differentiation; Cell Proliferation; Down-Regulation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Myeloid Cells; NADPH Oxidases; Phosphorylation; Principal Component Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins c-vav; Respiratory Burst; Roscovitine; Signal Transduction; src-Family Kinases; Tretinoin; Up-Regulation

2020